Source comparison
MT-1 vs Melanotan-II: The Real Comparison That Matters
The meaningful comparison isn't between MT-1 and Melanotan-1. It's between Melanotan-1 (MT-1) and Melanotan-II (MT-2). These are structurally and pharmacologically distinct peptides. Melanotan-1 is a linear 13-amino-acid sequence (Ser-Tyr-Ser-Nle-Glu-His-D-Phe
This comparison does not assign a generated winner or score.
- The meaningful comparison isn't between MT-1 and Melanotan-1. It's between Melanotan-1 (MT-1) and Melanotan-II (MT-2). These are structurally and pharmacologically distinct peptides. Melanotan-1 is a linear 13-amino-acid sequence (Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val) with selective MC1R affinity. Melanotan-II is a cyclic 7-amino-acid analog with a lactam bridge between positions 4 and 10, conferring non-selective binding to MC1R, MC3R, MC4R, and MC5R. This structural difference produces divergent pharmacological profiles.
- Amino Acid Count
- 13 (linear)
- 7 (cyclic, lactam bridge)
- MT-1 has longer half-life due to proteolytic resistance
- Receptor Selectivity
- MC1R-selective
- MC1R, MC3R, MC4R, MC5R (non-selective)
- MT-2 produces appetite suppression, sexual side effects
- Half-Life
- ~33 minutes (plasma), sustained via implant
- ~2–3 hours (subcutaneous injection)
- MT-1 requires controlled-release formulation for clinical use
- Approved Use
- EMA-approved for EPP (Scenesse)
- No regulatory approval anywhere
- MT-1 has established safety profile; MT-2 does not
- Melanogenesis Potency
- Moderate (10–50× α-MSH affinity)
- High (100–1000× α-MSH affinity at MC1R)
- MT-2 produces faster, darker pigmentation but higher side-effect risk
- Common Side Effects
- Nausea (10–15%), injection-site reactions
- Nausea (40–60%), spontaneous erections, flushing, appetite loss
- MT-2's MC4R activity causes central nervous system effects
- Melanotan-1 reached regulatory approval because its MC1R selectivity confined effects to melanocytes, producing predictable pigmentation without systemic complications. Melanotan-II's broader receptor activity introduced variables. Appetite changes, increased libido, potential cardiovascular effects. That complicated clinical development. When researchers reference MT-1, they're discussing a compound with a decade of post-market safety data. MT-2 remains an investigational peptide with no approved formulations.